AstraZeneca's Enhertu Drug Granted Breakthrough Therapy Designation in US
27 April 2022 - 9:04AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Wednesday that its Enhertu drug has been
granted a breakthrough therapy designation in the U.S. for the
treatment of an unresectable or metastic breast cancer.
The FTSE 100 pharma giant said that Enhertu has been now been
granted five breakthrough therapy designations, including three in
breast cancer and one in both lung and gastric cancers.
The trial showed significant improvement in survival, the
company said.
AstraZeneca developed Enhertu with Japanese pharmaceutical
company Daiichi Sankyo Co.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 27, 2022 02:49 ET (06:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024